The Patent Finder

Bioxcel Therapeutics, Inc.

18 patents currently held · Updated Nov 15, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

1
Ending by 2030
Jan 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 17, 2027
    The maintenance fee for Use of Sublingual Dexmedetomidine for the Treatment of Agitation (US 11,786,508) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
  • 2 fees due May 7, 2027
  • 1 fee due Jun 12, 2027
    The maintenance fee for Use of Sublingual Dexmedetomidine for the Treatment of Agitation (US 11,839,604) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
  • 1 fee due Aug 6, 2027
    The maintenance fee for Non-Sedating Dexmedetomidine Treatment Regimens (US 11,890,272) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
  • 1 fee due Sep 19, 2027
    The maintenance fee for Use of Sublingual Dexmedetomidine for the Treatment of Agitation (US 11,931,340) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 12,138,247Non-Sedating Dexmedetomidine Treatment Regimens
In force
 · Medium confidence
In forceMedium confidence
US 11,786,508Use of Sublingual Dexmedetomidine for the Treatment of Agitation
In force
 · Low confidence
In forceLow confidence
US 11,839,604Use of Sublingual Dexmedetomidine for the Treatment of Agitation
In force
 · High confidence
In forceHigh confidence
US 11,931,340Use of Sublingual Dexmedetomidine for the Treatment of Agitation
In force
 · High confidence
In forceHigh confidence
US 10,792,246Film Formulations Containing Dexmedetomidine and Methods of Producing Them
In force
 · High confidence
In forceHigh confidence
US 11,478,422Film Formulations Containing Dexmedetomidine and Methods of Producing Them
In force
 · High confidence
In forceHigh confidence
US 11,497,711Film Formulations Containing Dexmedetomidine and Methods of Producing Them
In force
 · High confidence
In forceHigh confidence
US 11,517,524Film Formulations Containing Dexmedetomidine and Methods of Producing Them
In force
 · Low confidence
In forceLow confidence
US 11,559,484Film Formulations Containing Dexmedetomidine and Methods of Producing Them
In force
 · High confidence
In forceHigh confidence
US 11,806,429Film Formulations Containing Dexmedetomidine and Methods of Producing Them
In force
 · High confidence
In forceHigh confidence
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
Also on record, not counted in the 18: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 21 abandoned · 1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited